Abstract
In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.
Cite
CITATION STYLE
Hanzel, J., Dreesen, E., Vermeire, S., Löwenberg, M., Hoentjen, F., Bossuyt, P., … Mathôt, R. (2022, May 1). Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143). Inflammatory Bowel Diseases. Oxford University Press. https://doi.org/10.1093/ibd/izab270
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.